21(R)-Hydroxy Montelukast (CAS 184763-26-6)
ACCÈS RAPIDE AUX LIENS
21(R)-Hydroxy Montelukast is a chemically modified derivative of montelukast, a leukotriene receptor antagonist, primarily distinguished by its specific hydroxylation at the 21st carbon in the R configuration. This structural alteration significantly influences its interaction with leukotriene receptors, potentially altering its affinity or selectivity compared to its parent compound. In research contexts, 21(R)-Hydroxy Montelukast serves as a tool for probing the biochemical pathways involved in leukotriene receptor signaling and regulation. Its unique properties enable scientists to dissect the nuanced mechanisms through which leukotrienes influence cellular responses, contributing to a deeper understanding of inflammatory processes at a molecular level. By offering a variant molecular structure, this compound aids in elucidating the role of specific leukotriene receptor subtypes in various signaling pathways, facilitating the exploration of their contributions to cellular and physiological responses in model organisms.
21(R)-Hydroxy Montelukast (CAS 184763-26-6) Références
- Sélection de la dose de montélukast chez les enfants de 6 à 14 ans: comparaison de la pharmacocinétique d'une dose unique chez les enfants et les adultes. | Knorr, B., et al. 1999. J Clin Pharmacol. 39: 786-93. PMID: 10434229
- Métabolisme in vitro du montélukast par les cytochromes P450 et les UDP-Glucuronosyltransférases. | Cardoso, Jde O., et al. 2015. Drug Metab Dispos. 43: 1905-16. PMID: 26374173
- Profils métaboliques du montélukast sodique (Singulair), un antagoniste puissant du récepteur cystéinyl leucotriène1, dans le plasma humain et la bile. | Balani, SK., et al. 1997. Drug Metab Dispos. 25: 1282-7. PMID: 9351905
Informations pour la commande
| Nom du produit | Ref. Catalogue | COND. | Prix HT | QTÉ | Favoris | |
21(R)-Hydroxy Montelukast, 500 µg | sc-206556 | 500 µg | $600.00 |